Clinical Trials Directory

Trials / Unknown

UnknownNCT02367547

Superficial Basal Cell Cancer's Photodynamic Therapy: Comparing Three Photosensitizers: HAL and BF-200 ALA Versus MAL

Superficial Basal Cell Cancer's Photodynamic Therapy: Comparing Three Photosensitizers: Hexylaminolevulinate and Aminolevulinic Acid Nano Emulsion Versus Methylaminolevulinate

Status
Unknown
Phase
Phase 1 / Phase 2
Study type
Interventional
Enrollment
117 (actual)
Sponsor
Joint Authority for Päijät-Häme Social and Health Care · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This pilot study compares three photosensitisers, hexylaminolevulinate (HAL) and aminolevulinic acid nano emulsion (BF-200 ALA) to methylaminolevulinate (MAL) in photodynamic therapy of superficially growing basal cell carcinomas. Study is conducted using randomised prospective double blinded comparing design. Fluorescence is measured in A.U. (Arbitrary Unit) with standardised set-up before and after the exposure. Efficacy is assessed clinically, histologically and by hyperspectral imaging system at 3 months, 12 months and 5 years.

Detailed description

Study recruits volunteering patients, who are referred to the department of dermatology and allergology, Päijät-Häme Central Hospital, Lahti, with 99 clinically assessed superficial basal cell carcinoma on the body area, not face and scalp. Diagnoses is confirmed histologically by punch biopsies and hyperspectral images are taken before the biopsies. The lesions are randomised in three groups: interventions HAL and BF-200 ALA and comparator MAL. Photodynamic therapy is given by the standard procedure. Fluorescence is measured in A.U. (Arbitrary Unit) with standardised set-up, with Wood's light, digital camera and a yellow lens, before and after the exposure. Pain is measured in VAS-scale before, during and after the exposure. Efficacy is assessed clinically, histologically and by hyperspectral imaging system at 3 months, 12 months and 5 years.

Conditions

Interventions

TypeNameDescription
DRUGHexylaminolevulinate creamThe cream is mixed up by the Pharmacy Yliopiston Apteekki for the study and every set is analysed by mass spectrometry.
DRUGAminolevulinic Acid Nano EmulsionIn the study we use Ameluz.
DRUGMethylaminolevulinate creamIn the study we use Metvix.

Timeline

Start date
2015-03-01
Primary completion
2018-09-01
Completion
2025-12-01
First posted
2015-02-20
Last updated
2019-03-28

Locations

1 site across 1 country: Finland

Source: ClinicalTrials.gov record NCT02367547. Inclusion in this directory is not an endorsement.